Clinicopathological values of PD-L1 expression in HER2-positive breast cancer

Several ongoing clinical trials are investigating the use of immuno-targeting therapy with programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) inhibitors for triple-negative breast cancer. However, the role of PD-L1 expression in HER2-positive breast cancer remains unclear. We inve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Inoue, Kenichi, Matsumoto, Hiroshi, Fujii, Takaaki, Horiguchi, Jun, Oyama, Tetsunari, Kurosumi, Masafumi, Shirabe, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853939/
https://www.ncbi.nlm.nih.gov/pubmed/31723167
http://dx.doi.org/10.1038/s41598-019-52944-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6853939/
https://www.ncbi.nlm.nih.gov/pubmed/31723167
http://dx.doi.org/10.1038/s41598-019-52944-6

Ejemplares similares